Shedding new light on the humble glass slide

Shedding new light on the humble glass slide

May 08, 2017

From Pathology in Practice:

Slides for success in tissue adhesion

Pathology in Practice looks into a simple but effective solution to stop tissue sections becoming detached and floating away when faced with harsh processing conditions typical of methods such as immunohistochemistry and in situ hybridization.

Read the full article at Pathology in Practice: Shedding new light on the humble glass slide

Trajan Series 3 Adhesive Microscope Slides
Image: Pathology in Practice cover featuring Trajan Series 3 Adhesive Microscope Slides

More information
Betsi Cadwaladr University Health Board
NHS Wales
Pathology in Practice
Trajan Microscope Slides

Media contact information
Trajan Scientific and Medical
media@trajanscimed.com
+44 (0) 1244 403 100

 




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More